-
Early detection of SARS-CoV-2 infection is critical to reducing the asymptomatic and pre-symptomatic spread of COVID-19.
- PCR testing is still considered by the FDA and CDC to be the “gold standard”. It is a more sensitive, accurate, and reliable diagnostic test compared to the rapid antigen lateral flow tests (LFT).
- Rapid antigen LFT tests continue to deliver unacceptably high rates of both false-negative and false-positive test results.
- Saliva-based PCR testing is able to detect the presence of COVID-19 with 99.98% accuracy days before symptoms appear due to the extraction and amplification process with results in under 24 hours.
- The patented and highly sensitive chemical formulation found only in the SDNA-1000, 2000, and 3000 saliva collection devices are able to detect infections from saliva samples measuring as low as 200 copies/ml compared to rapid antigen LFT requiring a minimum of 10,000-20,000 copies/ml.
- In addition, when compared to traditional swab PCR tests SARS-CoV-2 RNA first appears in saliva and then later in nasal-swab samples. A high-sensitivity (limit of detection of ∼10 3 copies/mL) RNA test detected SARS-CoV-2 virus in saliva 1.5 to 4.5 days before the viral load in the paired nasal-swab samples.(1)